FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008509462> ?p ?o ?g. }

• W2008509462 endingPage "260" @default.
• W2008509462 startingPage "247" @default.
• W2008509462 abstract "ABSTRACT Nitric oxide (NO), is known to exert vasodilatory, bronchodilatory, and antiplatelet effects, and quantitative or functional NO deficiency has been implicated in various cardio‐vascular and airway diseases. NO donors, which are drugs capable of releasing NO either spontaneously or tissue‐dependently, represent a way of increasing NO. Here, we review our current understanding of the NO donor, GEA 3175, 1,2,3,4‐oxatriazolium, 3‐(3‐chloro‐2‐methylphenyl)‐5‐[[(methylphenyl)sulphonyl]amino], hydroxide inner salt. GEA 3175 is a mesoionic 3‐aryl substituted oxatriazole‐5‐imine derivative, which is a potent, stable, slow releasing NO donor with important actions in various organ systems. In isolated guinea pig trachea, rat bronchi and bovine and human small bronchioles, GEA 3175 induces potent, long‐lasting relaxation. In vivo , in sensitized guinea pigs, GEA 3175 protects against antigen‐induced bronchoconstriction. GEA 3175 also exerts potent vasodilatory properties. In isolated human pulmonary arteries, GEA 3175 induces relaxation which is long‐lasting and more potent than in airways. In isolated systemic arteries, GEA 3175 is also a potent vasodilator. By intravenous infusion GEA 3175 reduces blood pressure similarly to nitroglycerin. Vascular and bronchiolar relaxations were shown to be mediated via NO dependent pathways. GEA 3175 is also a potent anti‐inflammatory agent. Functions of polymorphnuclear cells (PMNs) such as leucotriene B 4 (LTB 4 ) — synhesis, chemotaxis and superoxide (O − 2 ) production are inhibited by GEA 3175. GEA3175 also inhibits upregulation of E‐selectin in human umbilical vein endothelial cells (HUVECs) and hence adhesion of neutrophils. Another action of GEA 3175 on the endothelium is inhibition of prostacyclin release. Finally, GEA 3175 has been demonstrated to be an antiplatelet agent. Thrombin‐induced platelet aggregation was inhibited by GEA 3175 in a cyclic GMP‐ and vasodilator‐stimulated phosphoprotein (VASP)‐phosphorylation‐dependent manner. Thus, GEA 3175 has been demonstrated to exert bronchodilatory, pulmonary vasodilatory, antiplatelet as well as anti‐inflammatory actions. Given these actions GEA 3175 may represent a potentially useful drug. The exact mechanism whereby GEA 3175 releases NO is, however, still unknown. In addition, most of the studies so far have been performed in isolated tissue preparations. Clearly, further in vivo studies involving animal models are required to clarify safety issues and whether GEA 3175 can be used in the treatment of pulmonary hypertension and/or airway diseases." @default.
• W2008509462 created "2016-06-24" @default.
• W2008509462 creator A5000740797 @default.
• W2008509462 creator A5002319440 @default.
• W2008509462 creator A5009720710 @default.
• W2008509462 creator A5055874398 @default.
• W2008509462 creator A5078690624 @default.
• W2008509462 date "2006-09-01" @default.
• W2008509462 modified "2023-10-15" @default.
• W2008509462 title "Potential Protective Properties of a Stable, Slow‐releasing Nitric Oxide Donor, GEA 3175, in the Lung" @default.
• W2008509462 cites W1968949511 @default.
• W2008509462 cites W1970638489 @default.
• W2008509462 cites W1972300311 @default.
• W2008509462 cites W1974438231 @default.
• W2008509462 cites W1975961217 @default.
• W2008509462 cites W1977632511 @default.
• W2008509462 cites W1982481699 @default.
• W2008509462 cites W1984444103 @default.
• W2008509462 cites W1990347766 @default.
• W2008509462 cites W1991469545 @default.
• W2008509462 cites W1993547242 @default.
• W2008509462 cites W1999314503 @default.
• W2008509462 cites W2002256816 @default.
• W2008509462 cites W2003913161 @default.
• W2008509462 cites W2006705030 @default.
• W2008509462 cites W2012438626 @default.
• W2008509462 cites W2016305001 @default.
• W2008509462 cites W2017944609 @default.
• W2008509462 cites W2022212575 @default.
• W2008509462 cites W2022325044 @default.
• W2008509462 cites W2024804850 @default.
• W2008509462 cites W2026974493 @default.
• W2008509462 cites W2031284851 @default.
• W2008509462 cites W2032563526 @default.
• W2008509462 cites W2042642188 @default.
• W2008509462 cites W2044024715 @default.
• W2008509462 cites W2046071195 @default.
• W2008509462 cites W2054510493 @default.
• W2008509462 cites W2062683293 @default.
• W2008509462 cites W2072844101 @default.
• W2008509462 cites W2077814237 @default.
• W2008509462 cites W2079355407 @default.
• W2008509462 cites W2083116124 @default.
• W2008509462 cites W2085845212 @default.
• W2008509462 cites W2087612828 @default.
• W2008509462 cites W2088179070 @default.
• W2008509462 cites W2090112063 @default.
• W2008509462 cites W2092427534 @default.
• W2008509462 cites W2093069867 @default.
• W2008509462 cites W2094972994 @default.
• W2008509462 cites W2109654316 @default.
• W2008509462 cites W2152118462 @default.
• W2008509462 cites W2153319596 @default.
• W2008509462 cites W2321522617 @default.
• W2008509462 cites W62795438 @default.
• W2008509462 doi "https://doi.org/10.1111/j.1527-3466.2006.00247.x" @default.
• W2008509462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17214601" @default.
• W2008509462 hasPublicationYear "2006" @default.
• W2008509462 type Work @default.
• W2008509462 sameAs 2008509462 @default.
• W2008509462 citedByCount "20" @default.
• W2008509462 countsByYear W20085094622012 @default.
• W2008509462 countsByYear W20085094622014 @default.
• W2008509462 countsByYear W20085094622017 @default.
• W2008509462 countsByYear W20085094622021 @default.
• W2008509462 countsByYear W20085094622022 @default.
• W2008509462 countsByYear W20085094622023 @default.
• W2008509462 crossrefType "journal-article" @default.
• W2008509462 hasAuthorship W2008509462A5000740797 @default.
• W2008509462 hasAuthorship W2008509462A5002319440 @default.
• W2008509462 hasAuthorship W2008509462A5009720710 @default.
• W2008509462 hasAuthorship W2008509462A5055874398 @default.
• W2008509462 hasAuthorship W2008509462A5078690624 @default.
• W2008509462 hasConcept C120770815 @default.
• W2008509462 hasConcept C134018914 @default.
• W2008509462 hasConcept C150903083 @default.
• W2008509462 hasConcept C185592680 @default.
• W2008509462 hasConcept C202751555 @default.
• W2008509462 hasConcept C207001950 @default.
• W2008509462 hasConcept C2777411675 @default.
• W2008509462 hasConcept C519581460 @default.
• W2008509462 hasConcept C55493867 @default.
• W2008509462 hasConcept C71924100 @default.
• W2008509462 hasConcept C86803240 @default.
• W2008509462 hasConcept C98274493 @default.
• W2008509462 hasConceptScore W2008509462C120770815 @default.
• W2008509462 hasConceptScore W2008509462C134018914 @default.
• W2008509462 hasConceptScore W2008509462C150903083 @default.
• W2008509462 hasConceptScore W2008509462C185592680 @default.
• W2008509462 hasConceptScore W2008509462C202751555 @default.
• W2008509462 hasConceptScore W2008509462C207001950 @default.
• W2008509462 hasConceptScore W2008509462C2777411675 @default.
• W2008509462 hasConceptScore W2008509462C519581460 @default.
• W2008509462 hasConceptScore W2008509462C55493867 @default.
• W2008509462 hasConceptScore W2008509462C71924100 @default.
• W2008509462 hasConceptScore W2008509462C86803240 @default.
• W2008509462 hasConceptScore W2008509462C98274493 @default.
• W2008509462 hasIssue "3-4" @default.

• next